Who invested in MBX Biosciences

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$64Mraised across 1 round since 2024, from 1 source

Latest round: Series C, $64MAug 2024
Investors: 5

See who backed them

The rounds

Aug 2024
Series C$64M
Source recorded

Founders and team

From MBX Biosciences's own website and the SEC filings it signed: 12 on the team.

Steve HoerterChairman & Chief Executive Officer
Debra SojkaVice President, Regulatory Affairs
Tyler CarnerVice President, Finance
Jeff HeldChief Legal Officer
John SmitherChief Financial Officer
Karen BasbaumChief Business Officer
Mark HopeChief Regulatory & Quality Officer
Mark SouedChief Commercial Officer
Michelle GrahamChief Human Resources Officer
Peter Kent HawrylukExecutive Officer, Directori
Richard Kent DiMarchiExecutive Officer, Directori
Richard M. BartramExecutive Officeri

On the board, as filediCarl M. GordonEdward M. MathersJames M. Cornelius

Everyone who backed them

New Enterprise AssociatesVC firm1round

Norwest Venture PartnersVC firm1round

OrbiMedPrivate equity1round

RA Capital ManagementPrivate equity1round

Wellington ManagementVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists MBX Biosciences as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.